06:25 , Aug 10, 2018 |  BC Week In Review  |  Company News

Genprex to evaluate effect of Oncoprex on checkpoint inhibition with MD Anderson

Genprex Inc. (NASDAQ:GNPX) will sponsor a preclinical program at the University of Texas MD Anderson Cancer Center (Houston, Texas) aimed at evaluating the effect of Genprex's Oncoprex on checkpoint inhibitors, including anti-PD-1 and anti-CTLA-4 therapies....
17:47 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Amgen's Blincyto among negative CHMP opinions

EMA's CHMP released a handful of negative opinions July 27, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC...
20:34 , Jul 27, 2018 |  BC Extra  |  Company News

New Blincyto indication among negative CHMP opinions

EMA's CHMP released a handful of negative opinions Friday, including one for Blincyto blinatumomab from Amgen Inc. (NASDAQ:AMGN) and, on re-examination, negative recommendations for Dexxience betrixaban from Portola Pharmaceuticals Inc. (NASDAQ:PTLA) and Eladynos abaloparatide-SC from...
21:30 , Jul 26, 2018 |  BC Extra  |  Company News

CHMP says no to Opdivo + Yervoy for RCC

Bristol-Myers Squibb Co. (NYSE:BMY) revealed in its 2Q18 earnings call that EMA's CHMP plans to issue a negative opinion for Opdivo nivolumab plus Yervoy ipilimumab as first-line treatment of intermediate- and poor-risk patients with advanced...
22:04 , Jul 19, 2018 |  BC Innovations  |  Tools & Techniques

Immunotherapy Matchmaking

MD Anderson Cancer Center is using its access to patient samples to inject more rationality into decisions about which therapies should be paired with checkpoint inhibitors, and how to optimize the combos. The goal is...
19:53 , Jul 13, 2018 |  BC Week In Review  |  Clinical News

Opdivo plus Yervoy approved for mCRC

Bristol-Myers Squibb Co. (NYSE:BMY) said FDA granted accelerated approval to Opdivo nivolumab plus Yervoy ipilimumab to treat patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer...
18:52 , Jul 12, 2018 |  BC Innovations  |  Product R&D

All-in-one viruses

Having taken its lead oncolytic virus into the clinic, PsiOxus Therapeutics Ltd. is building an immuno-oncology platform that uses engineered versions of the vector to selectively target multiple genes at a time to tumor cells...
03:05 , Jun 30, 2018 |  BioCentury  |  Finance

Hidden in the rough

Judicious stock picking was especially important in the second quarter, as 57% of global biotech stocks saw their equity values decline. Volatility continued to roil global markets during the period and additional uncertainty looms with the...
02:02 , Jun 9, 2018 |  BioCentury  |  Product Development

POC for cytokines

A body of clinical evidence is emerging that two different approaches to immune-stimulating cytokine therapies could increase efficacy of PD-1 inhibitors in both hot and cold tumors. Oncologists who spoke to BioCentury said, taken together, data...
16:52 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

CytomX reports updated Phase I data for CX-072 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) reported updated data from the Phase I/II PROCLAIM-072 trial evaluating CX-072 as monotherapy and in combination with anti-CTLA-4 mAb Yervoy ipilimumab or BRAF inhibitor Zelboraf vemurafenib to treat metastatic or locally...